Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Brawley · SciRah

Researcher profile · Semantic Scholar

C. Brawley

Share profile

C. Brawley — researcher profile on SciRah

h-index: 17
Works: 32
Citations: 4,603

Most-cited papers

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. James, J. de Bono, M. Spears, N. Clarke +43 more
2017New England Journal of Medicine1,611 citations Open access
Semantic Scholar
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
C. Parker, N. James, C. Brawley, N. Clarke +38 more
2018The Lancet1,074 citations Open access
Semantic Scholar
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. Clarke, Adnan Ali, F. Ingleby, A. Hoyle +46 more
2019Annals of Oncology368 citations Open access
Semantic Scholar
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
C. Vale, D. Fisher, A. Kneebone, C. Parker +14 more
2020The Lancet351 citations Open access
Semantic Scholar
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
G. Attard, L. Murphy, N. Clarke, W. Cross +150 more
2021The Lancet321 citations Open access
Semantic Scholar
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
A. Hoyle, Adnan Ali, N. James, A. Cook +21 more
2019European Urology193 citations Open access
Semantic Scholar
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
Adnan Ali, A. Hoyle, Á. Haran, C. Brawley +13 more
2021JAMA Oncology121 citations Open access
Semantic Scholar
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
C. Parker, Nicholas D. James, C. Brawley, N. Clarke +42 more
2022PLoS Medicine103 citations Open access
Semantic Scholar
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
G. Attard, L. Murphy, N. Clarke, A. Sachdeva +51 more
2023The Lancet Oncology97 citations Open access
Semantic Scholar
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
C. Parker, H. Kynaston, A. Cook, N. Clarke +35 more
2024The Lancet68 citations Open access
Semantic Scholar
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
N. James, Noel W. Clarke, A. Cook, Adnan Ali +52 more
2022International Journal of Cancer59 citations Open access
Semantic Scholar
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
H. Rush, L. Murphy, A. Morgans, N. Clarke +33 more
2021Journal of Clinical Oncology54 citations Open access
Semantic Scholar
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.
E. Grist, P. Dutey-Magni, Marina A. Parry, L. Mendes +43 more
2025Cell34 citations Open access
Semantic Scholar
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
C. Gilson, F. Ingleby, D. Gilbert, M. Parry +21 more
2020JCO Precision Oncology30 citations
Semantic Scholar
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
E. Grist, S. Friedrich, C. Brawley, L. Mendes +28 more
2022Genome Medicine27 citations Open access
Semantic Scholar
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
N. James, F. Ingleby, N. Clarke, C. Amos +43 more
2022JNCI Cancer Spectrum21 citations Open access
Semantic Scholar
Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial.
H. Rush, A. Cook, C. Brawley, L. Murphy +12 more
202017 citations
Semantic Scholar
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
M. Parry, E. Grist, L. Mendes, P. Dutey-Magni +42 more
2023Research Square14 citations Open access
Semantic Scholar
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
Adnan Ali, A. Hoyle, C. Parker, C. Brawley +10 more
2020European Urology Oncology11 citations Open access
Semantic Scholar
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
C. Clarke, R. Hunter, A. Gabrio, C. Brawley +18 more
2022PLoS ONE10 citations Open access
Semantic Scholar
Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison”
S. Ali, A. Hoyle, N. James, C. Parker +7 more
2019Annals of Oncology9 citations Open access
Semantic Scholar
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. Clarke, A. Ali, F. Ingleby, A. Hoyle +46 more
2020Annals of Oncology5 citations Open access
Semantic Scholar
634P Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison” of the STAMPEDE trial
Á. Haran, Adnan Ali, A. Hoyle, T. Hambrock +10 more
20203 citations Open access
Semantic Scholar
Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE.
C. Parker, N. D. James, C. Brawley, N. Clarke +16 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.
C. Clarke, C. Brawley, F. Ingleby, A. Gabrio +10 more
20201 citations Open access
Semantic Scholar
Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial.
E. Grist, M. Parry, S. Friedrich, C. Brawley +16 more
20210 citations
Semantic Scholar
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. James, J. de Bono, M. Spears, N. Clarke +43 more
20210 citations
Semantic Scholar
Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.
L. Mendes, C. Brawley, E. Grist, Adnan Ali +16 more
20210 citations
Semantic Scholar
MP51-04 THE IMPORTANCE OF LYMPH NODE LOCATION, BURDEN AND TREATMENT OUTCOME IN M1 HSPC: ANALYSIS FROM THE STAMPEDE TRIAL ARMS A AND C
Á. Haran, Adnan Ali, A. Hoyle, T. Hambrock +10 more
20200 citations Open access
Semantic Scholar
Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
H. Mintz, C. Amos, R. Brannan, C. Brawley +12 more
2019Annals of Oncology0 citations Open access
Semantic Scholar
Radiotherapy for metastatic prostate cancer-Authors' reply.
C. Parker, N. James, C. Brawley, N. Clarke +1 more
2019The Lancet0 citations Open access
Semantic Scholar
in and metastatic sensitive : long-term results
N. Clarke, A. Ali, F. Ingleby, A. Hoyle +46 more
20190 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Sydes×26
Invite
M. Sydes — researcher profile on SciRah
N. Clarke×25
Invite
N. Clarke — researcher profile on SciRah
G. Attard×23
Invite
G. Attard — researcher profile on SciRah
N. James×19
Invite
N. James — researcher profile on SciRah

×18

Invite

S. Gillessen — researcher profile on SciRah

Invite

A. Hoyle — researcher profile on SciRah

Invite

C. Amos — researcher profile on SciRah

Invite

M. Parmar — researcher profile on SciRah

Invite

R. Millman — researcher profile on SciRah

D. Dearnaley×15

Invite

D. Dearnaley — researcher profile on SciRah

D. Matheson×15

Invite

D. Matheson — researcher profile on SciRah

Invite

M. Mason — researcher profile on SciRah